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1. Introduction 
The development of a new drug is a long, expensive and complex process which aims to 
identify a pharmacologically-active low toxicity drug candidate. Large amount of resources 
and time are wasted if a drug fails in late stages of development or is withdrawn from the 
market because of toxicity. Hepatotoxicity in particular is a frequent cause for the failure of 
a drug to get approved, or for the withdrawal of already marketed medicines (Stevens & 
Baker, 2009). Current preclinical testing systems lack predictivity and need to be 
significantly improved in order to allow the identification of potentially hepatotoxic drug 
candidates, and the safety-based prioritization of compounds early in the development 
process. A cost-effective identification of compounds with potential liver liabilities in the 
initial preclinical phase of drug development would undoubtedly reduce the number of 
drug nonapprovals and withdrawals. 
We present here the development of an optimized methodology for predicting drug-
induced hepatotoxicity, which could be used early in the drug development process (e.g. 
during lead optimization), relying on the assessment of multiple cellular readouts by high-
throughput flow cytometry. 
This methodology is based on the measurement of key intracellular events reflecting the 
main cellular and metabolic changes occurring in hepatocytes in response to hepatotoxicant 
exposition (i.e. cytolysis, mitochondrial membrane depolarization, NAD(P)H depletion, 
ROS production, glutathione (GSH) depletion, and variations in lipid content). Each 
measurement was optimized in terms of robustness (reproducibility), sensitivity and 
dynamic range, and when possible multiplexed, in 3 hepatic cellular models: the HepG2 cell 
line, fresh rat hepatocytes and cryopreserved human hepatocytes. 
The HepG2 cell line, derived from a human hepatoma, is probably the most utilized cell line 
in hepatotoxicological studies. HepG2 cells are attractive because they are cheap, easy to 
handle and generate reproducible results. However, they are known to have a reduced drug 
metabolizing activity compared to primary hepatocytes. Fresh primary rat hepatocytes 
provide a model of fully functional hepatocytes, well suited to flow cytometry experiments, 
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although the results obtained are not always relevant to human, due to species differences 
in metabolism and cell biology between rat and man. Primary human hepatocytes are 
considered the “gold standard” but the reduced viability of frozen human hepatocytes and 
the significant donor-to-donor variability both in terms of quality and metabolic activity, as 
well as their restricted availability constitute important limiting factors for their extensive 
use. Nevertheless, these biological systems with their inherent advantages and flaws are the 
methods of choice for in vitro assessment of hepatotoxicity. The high-throughput flow 
cytometry approach presented here is applicable to all these biological test systems. 
2. Drug testing process 
The entire drug testing process (from the seeding of the cells until the flow cytometry 
analysis) was performed in 96-well plates. Each step of this process was optimized. First the 
cell density and the medium composition were adjusted for each cell type in order to obtain 
a confluent monolayer of hepatocytes with high viability. 
  
HepG2 cell line Rat hepatocytes Human hepatocytes 
 
Fig. 1. Hepatic cellular models 
HepG2 cells (left), freshly isolated primary rat hepatocytes (middle), and cryopreserved 
human hepatocytes (right) were observed 72 h post-seeding in 96-well plates. Nuclei (in 
blue) were stained with Hoechst 33342 and mitochondria (in red) of viable cells were stained 
with the potentiometric probe TMRM (scale bar = 50µm). 
The cell detachment process was adapted to each cellular model and its innocuousness was 
checked by comparing flow cytometry results on suspended cells with imaging results on 
adherent cells. 
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Fig. 2. Innocuousness of the cell detachment process 
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The cell viability of rat hepatocytes and HepG2 cells after 48 h in culture was assessed on 
adherent cells in microscopy and after cell detachment in flow cytometry (on suspended 
cells). Viable cells were identified by staining polarized mitochondria with a potentiometric 
probe. Results are expressed as the mean ± SD of 3 replicates. 
In addition, several probes and staining protocols were tested for each functional assay in 
order to maximize the dynamic range (signal/noise ratio) of the measurement, and to 
ensure sufficient signal stability over time (compatible with flow cytometry analysis). 
Flow cytometry experiments were performed using a special order BD LSRFortessa™ cell 
analyzer equipped with 3 excitation sources (355 nm, 488 nm, and 561 nm) and a high-
throughput injection module capable of handling 96-well plates. In our customized 
configuration, the instrument allows the simultaneous detection of up to 10 colors. As the 
optical filters are removable and interchangeable, this flow cytometer has the flexibility to 
support a large variety of multicolor flow cytometry assays, which allowed us to multiplex 
most of the assays we developed. Analysis of flow cytometry outputs was performed using 
BD FACSDiva software. Typically a few thousands cells per well were analyzed, and the 
wells in which less than 100 cells could be analyzed were rejected. 
Thanks to the extensive optimization of the entire drug testing process, we were able to 
develop robust and sensitive assays with low variability, in all 3 cellular models. This 
allowed us to generate accurate data by performing experiments in duplicate (2 replicates 
per experimental condition). Both the multiplexing of assays and the use of a reduced 
number of experimental replicates contribute to the high throughput of the assay, required 
for the rapid testing of numerous compounds in the early stage of drug development. 
Although the functional assays we developed were multiplexed, they are presented 
separately for easier understanding. 
3. Cell death measurements 
Cytolysis is a conventional cytotoxicity indicator. Indeed, loss of plasma membrane integrity 
is a measure of cell death and quantitates a general cytotoxicity that is not necessarily 
unique to liver. In our experiments, cytolysis is assessed with a fluorescent high affinity 
nucleic acid stain that easily penetrates cells with compromised plasma membranes but do 
not cross healthy cell membranes. It is thus very easy to distinguish fluorescent cytolytic 
cells from non-fluorescent viable cells in flow cytometry. 
The loss of the mitochondrial inner transmembrane potential (Δψ) maintained by the 
respiratory chain can be triggered by many different drug-induced toxic mechanisms, 
leading to cell death either by apoptosis or by necrosis. 
Mitochondrial potential can be readily measured with fluorescent cationic dyes 
(rhodamines, carbocyanines, etc.). The accumulation of these amphiphilic cationic probes is 
dependent on the mitochondrial potential value, and thus cells with active mitochondria 
(high Δψ) will brightly fluoresce whereas cells in which mitochondria are depolarized (low 
Δψ) will be barely fluorescent. 
Cytolysis and mitochondrial transmembrane potential measurements were optimized in the 
3 cellular models using acetaminophen (APAP) as a model compound for drug-induced 
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hepatotoxicity. APAP is widely used for the treatment of pain and fever. Although it is safe 
and effective at therapeutic levels, the drug causes severe liver injury following overdosing 
(whether on purpose or by accident) with the potential to progress to liver failure (Tang, 
2007). Partly because of its widespread use, APAP hepatotoxicity accounts for more than a 
third of drug-related acute liver failure cases in the US. 
The results obtained in the mitochondrial depolarization assay after 24 h of treatment with 
acetaminophen are very similar to those obtained in the cytolysis assay. In rat hepatocytes, 
the EC50 is slightly lower in the mitochondrial assay compared to the cytolysis assay, and 
there is no significant difference between EC50 for mitochondrial depolarization and 
cytolysis in HepG2 cells or human hepatocytes. 
 Cytolysis
10 -5 10 -4 10 -3 10 -2 10 -1
0
20
40
60
80
100
[APAP] (M)
%
 o
f 
cy
to
ly
ti
c 
ce
ll
s
Mitochondrial depolarization
10 -5 10 -4 10 -3 10 -2 10 -1
0
20
40
60
80
100
HepG2
Rat hepatocytes
Human hepatocytes
[APAP] (M)
%
 o
f 
ce
ll
s 
w
it
h
 l
o
w
Δψ
 
Fig. 3. Acetaminophen-induced cell death in hepatocytes 
Primary human hepatocytes, primary rat hepatocytes and HepG2 cells were incubated for 
24 h with increasing concentrations of acetaminophen. Cytolysis and mitochondrial membrane 
depolarization were measured in high-throughput flow cytometry with SYTOX Green and 
TMRM respectively. Results are expressed as the mean ± SD of 2 replicates. Sigmoidal curve 
fitting was performed with GraphPad Prism software. 
The EC50 of the curves representing the percentage of non-viable cells after 24 h of 
treatment with acetaminophen are very similar from one cell type to another. The 3 
cellular models are thus equally sensitive to acetaminophen cytotoxicity. In contrast the 
signal/noise ratio differs greatly between cellular models. This is the direct consequence 
of the differences in the cytolysis rate in basal (vehicle-treated) conditions: less than 10% 
in HepG2 cells, around 25% in primary rat hepatocytes and more than 60% in 
cryopreserved human hepatocytes. Note that the basal percentage of non viable cells after 
48 h in culture (which determines the dynamic range of the cell death assays) varies 
substantially (from 30% to 80% in our tests) from one batch of cryopreserved human 
hepatocytes to another (not shown). 
More than 80 other drugs were tested and gave similar results in the cytolysis assay and in 
the mitochondrial depolarization assay, confirming that both are direct indicators of cell 
death. 
Regarding the relationship between in vitro cell death induction and clinically observed 
drug-induced hepatotoxicity, we show here the results obtained with two drugs which are 
considered non-hepatotoxic, namely metformin and entacapone (Fig. 4). 
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Metformin, an orally available biguanine derivative, is a cornerstone for the treatment of 
type 2 diabetes, in particular in overweight and obese people. Metformin is safe, cost effective 
and remains the first line of diabetes therapy with diet and exercise (Andujar-Plata et al., 
2011). The drug may also be used in polycystic ovary syndrome (PCOS), non-alcoholic fatty 
liver disease (NAFLD) and premature puberty, three other conditions that feature insulin 
resistance. Although metformin mechanism of action is not well understood, it includes a 
decrease of hepatic insulin resistance and a change in bile acids metabolism. As expected for 
a safe drug, no toxicity of metformin was evidenced in our cell death assays (cytolysis and 
mitochondrial depolarization) after 24 h of treatment, in all three cellular models. 
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Fig. 4. Assessment of cell death induced by non-hepatotoxic drugs 
Primary human hepatocytes, primary rat hepatocytes and HepG2 cells were incubated for 
24 h with increasing concentrations of metformin or entacapone. Cell death was quantified 
in high-throughput flow cytometry by measuring mitochondrial membrane depolarization. 
Results are expressed as the mean ± SD of 2 replicates. Sigmoidal curve fitting was 
performed with GraphPad Prism software. 
Entacapone is a catechol-O-methyl transferase (COMT) inhibitor used in the treatment of 
Parkinson's disease. It is usually administered in conjunction with the dopaminergic agent 
L-DOPA in order to increase its bioavailability by preventing COMT from metabolizing L-
DOPA into 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD). Entacapone is often used in 
hepatotoxicological studies in parallel with tolcapone, another COMT inhibitor with liver 
liabilities, to form a model drug pair: “non-liver toxic drug” (entacapone) versus 
“hepatotoxic drug” (tolcapone). In our assays, entacapone elicited mitochondrial 
depolarization in primary hepatocytes after 24 h of treatment at the highest tested 
concentration of 200 µM (Fig. 4). However, no effect was observed in HepG2 cells in the 
same experimental conditions evidencing differences in susceptibility to entacapone-
induced toxicity between the primary cells and the HepG2 cell line. The fact that entacapone 
induces cell death in primary hepatocytes is not incompatible with the fact that it is a safe 
drug. Indeed as Paracelsus pointed out 500 years ago, the dose makes the poison, and all 
drugs can be toxic at high enough concentrations. What determines whether a drug is safe 
or not is the difference between the therapeutically active dose and the toxic dose, in other 
words, the safety margin of the drug. 
By measuring mitochondrial depolarization or cytolysis, we could determine the exposure 
levels that lead to cell death in vitro. Using lower doses, we could explore earlier indicators 
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of toxicity which are more hepato-specific and reflect the initial cellular processes that may 
lead to cell death. 
4. Energetic metabolism and oxidative stress measurements 
To improve sensitivity of the assay, we chose to measure NAD(P)H depletion, ROS 
production and glutathione depletion as earlier indicators of toxicity. 
Nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide 
phosphate (NADP+) are two of the most used coenzymes in cellular metabolism. They can 
exist in two different redox states (reduced and oxidized) that change into each other by 
accepting or donating electrons. The balance between the oxidized and reduced forms of 
these coenzymes is an important component of what is called the redox state of a cell, a 
measurement that reflects both the metabolic activity and the health of cells. 
Hundreds of enzymes use NAD(P)+ to catalyze reduction-oxidation reactions reversibly. 
Some of these are among the most abundant and well-studied enzymes participating in 
energetic metabolism (glycolysis, Krebs cycle, Lynen helix), biosynthesis, degradation, 
defense against oxidative damage, etc. 
The reduced and oxidized forms of these coenzymes have distinct fluorescence 
characteristics: NADH and NADPH are fluorescent, while their oxidized forms (NAD+ and 
NADP+ respectively) are not. Fluorescence signals consistent with NAD(P)H can be 
measured to monitor cellular activity through redox status. As a cell changes its metabolic 
activity, the balance between NAD(P)H and NAD(P)+ shifts correspondingly as the 
reduction-oxidation (redox) state of the cell fluctuates. 
In our experiments, cells are measured in suspension and thus there are little effects of 
absorption and morphology on fluorescence emission. The sole contributors are intracellular 
fluorophores (in this case, endogenous fluorescence). Autofluorescence signals consistent 
with NAD(P)H are measured to monitor energetic metabolism through redox status. The 
use of flow cytometry is of real advantage because NADH has a very short fluorescence 
lifetime (0.4 nanoseconds) and cannot be easily quantified by fluorescence microscopy. 
The NADH quantitation assay is attractive because, as it relies on cell autofluorescence and 
no staining step is required, it is cheap and quickly performed. In particular we used this 
assay to characterize batches of cryopreserved human hepatocytes (Fig. 5). 
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Fig. 5. Characterization of cryopreserved human hepatocytes batches 
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The quality of 7 different batches (i.e. donors) of human hepatocytes was assessed by 
measuring NADH depletion in high-throughput flow cytometry (excitation 355 nm – emission 
450±20 nm) after 3 days in culture. Results are expressed as the mean ± SD of 2 replicates. 
We generated dose-response curves for 25 chemicals, which all showed almost identical 
NADH depletion and mitochondrial depolarization results. However, a stronger NADH 
depletion than mitochondrial depolarization was evident for a few chemicals, including 
Alpha-naphtylisotiocianate (ANIT) (Fig. 6). 
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Fig. 6. NADH depletion “precedes” mitochondrial depolarization 
Primary rat hepatocytes were incubated for 48 h with the indicated concentrations of ANIT. 
NADH depletion and mitochondrial membrane depolarization were measured in high-
throughput flow cytometry as mentioned above. Results are expressed as the mean ± SD of 
2 replicates.  
ANIT is a known hepatotoxicant used in rodents to model human intrahepatic cholestasis. 
Cholestasis is the disruption of bile flow from the liver to the duodenum which leads to the 
accumulation of bile acids and other bile components in the liver and, ultimately, 
hepatobiliary toxicity. Cholestasis is often divided into two categories, extrahepatic and 
intrahepatic, based upon etiology. Extrahepatic cholestasis is the consequence of a 
mechanical blockage in the duct system (typically observed in patients with gallstones or 
tumors of the common biliary tract) whereas intrahepatic cholestasis is caused by 
physiological and pathological factors including genetic defects and chemicals. In rats, a 
single administration of ANIT induces intrahepatic cholestasis through damage to biliary 
epithelium cells (Orsler et al., 1999). 
Measuring NADH depletion results in only a small improvement in sensitivity compared to 
cytolysis and mitochondrial depolarization. Perhaps the high correlation between the 3 
assays is in part due to the fact that measurements are performed after 24 hours of 
treatment. Shorter exposures may be needed to increase the differences between these 
readouts. 
Oxidative stress is an important mechanism of drug-induced toxicity. Oxidative stress is 
characterized by both increased production of oxidants or free radicals, and intracellular 
macromolecular change due to oxidative injury such as decreased glutathione. 
Oxidative stress was first assessed by measuring intracellular levels of reactive oxygen 
species (ROS). ROS are molecules or ions (e.g. singlet oxygen, superoxides, peroxides, 
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hydroxyl radical, and hydroperoxides) formed by the incomplete one-electron reduction of 
oxygen. ROS form as a natural byproduct of the normal metabolism of oxygen and have 
important roles in cell signaling and homeostasis. However ROS levels can increase 
dramatically under different conditions of cell stress. The accumulation of these strong 
oxidants can result in significant damage to cell structures. Among the most important of 
these are the actions of free radicals on the fatty acid side chains of lipids in the various 
membranes of the cell, especially mitochondrial membranes (which are directly exposed to 
the superoxide anions produced during cellular respiration). 
Most of the commercially available probes to monitor ROS production by flow cytometry in 
living cells are cell-permeant chemicals that undergo changes in their fluorescence spectral 
properties once oxidized by ROS. Two different probes were used in our assay: 
dihydroethidium (DHE, also called hydroethidine) and CM-H2DCFDA (chloromethyl-
dichlorodihydrofluorescein diacetate). DHE exhibits blue fluorescence in the cytosol until 
oxidized by superoxide to 2-hydroxyethidium which intercalates within the DNA staining 
the cell nucleus a bright fluorescent red. In contrast the nonfluorescent CM-H2DCFDA is 
first hydrolyzed to DCFH in the cell by intracellular esterases and DCFH is oxidized to form 
the highly fluorescent DCF in the presence of ROS such as hydrogen peroxide. 
We applied the ROS production assay to many drugs including troglitazone, a 
thiazolidinedione which was approved in 1997 for the treatment of type 2 diabetes. 
Troglitazone was an effective antidiabetic drug with a fundamentally new mechanism of 
action but several cases of liver injury and failure were reported in troglitazone-treated 
patients. The drug was eventually withdrawn from the market in 2000, after the approval of 
a newer generation of thiazolidinediones (i.e. rosiglitazone and pioglitazone) with 
diminished incidence of toxicity. Since then, a significant effort has been made to elucidate 
the mechanisms underlying troglitazone-induced hepatotoxicity. Possible mechanisms of 
troglitazone-induced cell injury include the formation and accumulation of toxic 
metabolites, mitochondrial dysfunction and oxidant stress, ATP depletion and subsequent 
cell death (Tang, 2007). 
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Fig. 7. ROS production “precedes” mitochondrial depolarization 
HepG2 cells were incubated for 72 h with the indicated concentrations of troglitazone. ROS 
production and mitochondrial membrane depolarization were measured in high-
throughput flow cytometry as mentioned above. Results are expressed as the mean ± SD of 
2 replicates.  
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As shown in Fig. 7, after 72 h of treatment with troglitazone in HepG2 cells, a significant 
mitochondrial depolarization could be evidenced but only at the highest tested 
concentration of 200 µM. In contrast a significant ROS production was detected at a 
concentration of 40 µM. This pre-lethal assay is thus sensitive enough to detect ROS 
production at lower troglitazone concentrations than those needed for cytotoxicity. 
Oxidative stress was also assessed by quantifying intracellular glutathione (GSH) levels. 
Glutathione (a tripeptide composed of three amino acids: cysteine, glutamic acid, and 
glycine) is the most abundant and important nonprotein thiol in mammalian cells. 
Glutathione plays a major role in the protection of the liver against several hepatotoxicants. 
Indeed, in addition to its central role in protecting cells of all organs against damage 
produced by free radicals, glutathione is involved in drug detoxification. 
Xenobiotics including drugs are subject to metabolism which most likely acts as a self-
defense mechanism of the body. Drugs are metabolized through a complex series of 
biochemical reactions which are categorized into two major pathways, referred to as Phase I 
(oxidative reactions) and Phase II (conjugation reactions). This can result in toxification or 
detoxification (the activation or deactivation respectively) of the chemical. While both 
toxification and detoxification occur, the major metabolites of most drugs are detoxification 
products. 
During phase I and phase II, drugs are converted into more polar products that can be 
excreted in the urine or the bile depending on the particular characteristics of the end 
product. In phase I a variety of enzymes acts to introduce reactive and polar groups into 
their substrate. These reactions are mainly catalyzed by cytochrome P450 enzymes (often 
abbreviated as CYPs), amine oxidase, peroxidases, and flavin-containing monooxygenase. 
The cytochrome P450 superfamily is a large and diverse group of enzymes which catalyze 
the oxidation of organic substances. CYPs are the major enzymes involved in drug 
metabolism accounting for about 75% of the total number of different metabolic reactions. A 
significant side effect of phase I oxidative metabolism is the formation of potentially harmful 
reactive electrophiles which are mostly neutralized by glutathione that is in turn oxidized to 
glutathione disulfide (GSSG). Phase 2 reactions, also known as conjugation reactions, are 
usually detoxificating in nature and consist in the conjugation of phase I metabolites with 
charged species such as glutathione, sulfate, glycine or glucuronic acid. The conjugates 
formed are highly hydrophilic, which promotes their excretion. In this process, reduced 
glutathione levels decrease at the expense of the formation of glutathione conjugates. Thus 
GSH plays a key role in drug metabolism and depletion of reduced form of glutathione was 
reported to be a marker of hepatotoxicity (Xu et al., 2004). 
In our experiments, reduced glutathione content was assessed with monochlorobimane. 
This non fluorescent bimane derivative reacts with GSH (but do not react with GSSG) to 
form a highly fluorescent conjugated product readily quantified in viable cells by flow 
cytometry. 
The measurement of GSH in the 3 cellular models was first optimized using buthionine 
sulfoximine (BSO) which inhibits GSH neosynthesis thus reducing cellular GSH levels. The 
quantitation of GSH levels was restricted to non cytolytic cells (Fig. 8) based on cell 
morphology using the forward and side scatter channels (FSC and SSC) which are related to 
the cell size and the internal complexity respectively. 
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Fig. 8. Analysis of flow cytometry outputs for the GSH depletion assay 
Biparametric cell morphology plots show the selection of non-cytolytic HepG2 cells 
incubated with solvent (left plot) or 300 µM BSO (middle plot) for 72 h. The decrease in the 
fluorescence intensity of monochlorobimane staining after treatment with BSO is clearly 
visible in the overlay of the fluorescence outputs from both conditions (right plot): the 
fluorescence of the non-cytolytic solvent-treated cells (in grey) is more intense than the 
fluorescence of the non-cytolytic BSO-treated cells (in orange). 
As only viable cells are analyzed, the obtained dynamic range is high in all tested cell types 
(Fig. 9), even in cryopreserved human hepatocytes. After 24 hours of treatment with 300 µM 
BSO, a complete depletion in GSH is observed in all cellular models. However the EC50 of 
glutathione depletion is lower in HepG2 cells than in primary hepatocytes revealing 
differences in kinetics of GSH depletion between the cell line and the primary cells. 
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Fig. 9. Optimization of the GSH depletion assay with BSO 
Primary human hepatocytes, primary rat hepatocytes and HepG2 cells were incubated for 
24 h with increasing concentrations of BSO. GSH depletion was measured in high-
throughput flow cytometry as mentioned above. Results are expressed as the mean ± SD of 
2 replicates. Sigmoidal curve fitting was performed with GraphPad Prism software. 
Acetaminophen hepatotoxicity is mediated by the formation of NAPQI (N-acetyl-p-
benzoquinone imine), a reactive metabolite produced by a minor APAP clearance pathway 
mainly catalyzed by CYP2E1. Because of its chemical reactivity, NAPQI undergoes a 
conjugation with GSH. When large quantities of APAP are metabolized, the amount of 
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hepatic GSH is not sufficient to detoxify NAPQI. Glutathione pools are depleted and the 
reactive metabolite accumulates and binds to critical mitochondrial proteins ultimately 
causing cell death. Intracellular events resulting in hepatocyte death may include: 
disturbance of cellular calcium homeostasis, mitochondrial oxidative stress, collapse of 
mitochondrial membrane potential, decreased ATP synthesis, DNA fragmentation, and 
cytolysis (Tang, 2007). 
After 24 hours of treatment with 10 mM acetaminophen, a significant proportion of GSH-
depleted cells is observed in primary hepatocytes (from rat and human). However no GSH 
depletion is detected in the HepG2 cell line (Fig. 10). 
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Fig. 10. Acetaminophen-induced GSH depletion in hepatocytes 
Primary human hepatocytes, primary rat hepatocytes and HepG2 cells were incubated for 
24 h with increasing concentrations of APAP. GSH depletion was measured in high-
throughput flow cytometry as mentioned above. Results are expressed as the mean ± SD of 
2 replicates. Sigmoidal curve fitting was performed with GraphPad Prism software. 
Acetaminophen-induced glutathione depletion is a CYP-dependent mechanism and HepG2 
cells are known to have a reduced metabolic activity. The absence of glutathione depletion 
in the cell line is thus probably due to a reduced or inexistent formation of NAPQI. But 
interestingly acetaminophen is as toxic in HepG2 cells as it is in primary cells, as far as cell 
death is concerned (Fig. 3). Therefore the intracellular events leading to cell death in 
response to acetaminophen exposure appear to be different in HepG2 cells and primary 
hepatocytes, suggesting that a “non canonical” mechanism of action is involved in APAP-
induced cell death in the cell line. 
5. Lipid content measurement 
Drug-induced liver injury encompasses a large spectrum of lesions, some of which are the 
consequence of steatosis and phospholipidosis.  
Drugs are known to be able to induce steatosis, an abnormal accumulation of neutral lipids 
which can lead to liver failure. When fat accumulates, lipids are primarily stored as 
triglycerides. Steatosis is believed to result from an imbalance between hepatic free fatty 
acids inflow and triglyceride synthesis and excretion. Steatosis most often occurs in the liver 
which is the primary organ of lipid metabolism, although it may occur in any organ, such as 
the kidneys, heart, and muscles. The risk factors associated with steatosis are varied, and 
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include diabetes mellitus, hypertension and obesity. Macrovesicular steatosis, characterized 
by the presence of large lipid vesicles that displace the nucleus of hepatocytes, is the most 
common form of fatty degeneration, and may be caused by oversupply of lipids due to 
obesity, insulin resistance, or alcoholism. Microvesicular steatosis, the accumulation of 
multiple small lipid droplets, can be caused by several diseases including Reye’s  syndrome 
and hepatitis D. Fat accumulation is not necessarily a pathological condition and drug-
induced steatosis is often reversible. 
Prolonged exposure to certain drugs can cause macrovesicular steatosis, a benign hepatic 
lesion. Nevertheless chronic macrovesicular steatosis can evolve in certain cases into 
steatohepatitis (a liver inflammation resulting from steatosis) and ultimately into cirrhosis. 
Moreover, in a few patients, some drugs induce microvesicular steatosis which can 
potentially lead to liver failure with fatal consequences. 
One of the major mechanisms involved in drug-induced liver steatosis is the inhibition of 
beta-oxidation (degradation of long chain fatty acids) either by direct inhibition of 
mitochondrial beta-oxidation enzymes or by sequestration of the cofactors involved in this 
metabolic pathway. Other drugs eventually reduce beta-oxidation as a result of 
mitochondrial dysfunction (because the oxidized cofactors NAD+ and FAD which are 
produced by mitochondrial respiration are needed for beta-oxidation). 
Mitochondrial dysfunction plays a key role in the pathophysiology of steatohepatitis. 
Indeed, respiratory chain deficiency results in decreased ATP formation and increased ROS 
generation. The combination of decreased beta-oxidation (resulting in lipid accumulation) 
and increased ROS generation (resulting in lipid peroxidation and release of aldehydic 
derivatives with detrimental effects on hepatocytes) is an important mechanism of drug-
induced steatohepatitis. 
Phospholipidosis is a lysosomal storage disorder characterized by the excess accumulation 
of phospholipids in cells. The mechanisms of drug-induced phospholipidosis involve 
trapping or selective uptake of the phospholipidosis-inducing drugs within the lysosomes 
and acidic vesicles of affected cells. Drug trapping is followed by a gradual accumulation of 
drug-phospholipid complexes within the internal lysosomal membranes. The increase in 
undigested materials results in the abnormal accumulation of multi-lammellar bodies 
(myeloid bodies) in tissues. Many cationic amphiphilic drugs, including anti-depressants 
and cholesterol-lowering agents, are reported to cause drug-induced phospholipidosis in 
animals and humans. 
Phospholipidosis is often accompanied with various associated toxicities in the liver. It does 
not per se constitute frank toxicity but is reportedly predictive of drug or metabolite 
accumulation in affected tissues (Xu et al., 2004). 
Thus, the variations in both neutral lipids content and polar lipids (phospholipids) content 
may be early indicators of drug-induced hepatotoxicity. Various probes are available for use 
in intact cells that either titrate the lipid pool of interest or get accumulated as a lipid 
mimetic. We developed a proprietary probe formulation and detection methodology 
(lipotracker) that allows the simultaneous quantitation of neutral lipids and polar lipids 
(quantitation service available at www.fluofarma.com). The ratio of neutral lipids content 
upon polar lipids content at the single cell level is directly generated by the flow cytometry 
platform. This lipid ratio can be used to normalize cell size and dye uptake and provides a 
www.intechopen.com
 
High-Throughput Flow Cytometry for Predicting Drug-Induced Hepatotoxicity 
 
55 
reliable and precise measurement. As it has a very low variability it allows the detection of 
slight variations in lipid content. By using FSC and SSC outputs, lipid content is only 
measured in intact (non-cytolytic) cells, as it is the case for the glutathione depletion assay. 
The lipid content assay was first optimized with valproic acid (2-n-propylpentanoic acid), a 
drug commonly prescribed worldwide in the treatment of epilepsy and in the control of 
several types of seizures affecting both children and adults. The mechanism of the 
antiepileptic action of VPA involves the regional changes in the concentration of the 
neurotransmitter gamma-aminobutyric acid (GABA). VPA is well tolerated by the vast 
majority of patients but it can induce severe and sometimes fatal hepatotoxicity that is 
characterized by microvesicular steatosis and most likely results from beta-oxidation 
inhibition. 
A prerequisite to beta-oxidation is the uptake of fatty acids by mitochondria. Short- and 
medium-chain fatty acids may pass through the mitochondrial membrane directly, whereas 
long-chain fatty acids are transported across the mitochondrial membrane by a 
CoA/carnitine-dependent carrier system. Through several mechanisms, valproic acid 
inhibits the CoA/carnitine-dependent transport of fatty acids resulting in their 
accumulation in the cytoplasm. Besides a few valproic acid metabolites are suspected to 
directly inhibit specific enzyme(s) in the beta-oxidation pathway (Tang, 2007). 
Consistent with its known steatotic potential, VPA induces an increase in the lipid ratio, and 
this increase is identical in the 3 studied cell types after 24 h of treatment (Fig. 11). 
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Fig. 11. Valproate-induced variations in lipid content after short exposure 
Primary human hepatocytes, primary rat hepatocytes and HepG2 cells were incubated for 
24 h with increasing concentrations of VPA. Variations in lipid content were assessed by 
measuring the single cell lipid ratio (neutral lipids / polar lipids) in high-throughput flow 
cytometry as mentioned above. Results are expressed as a percentage of the control value 
(solvent-treated cells) and correspond to the mean ± SD of 2 replicates. Sigmoidal curve 
fitting was performed with GraphPad Prism software. 
In contrast, with a longer exposure to VPA, the observed effects are significantly different 
from one cellular model to another (Fig. 12). 
Primary hepatocytes (from human and rat) and HepG2 cells were incubated with increasing 
concentrations of VPA for 48 h or 72 h respectively. Variations in lipid content were assessed 
by measuring the single cell lipid ratio (neutral lipids / polar lipids) in high-throughput  
www.intechopen.com
 
Clinical Flow Cytometry – Emerging Applications 
 
56 
Lipid content
10 -5 10 -4 10 -3 10 -2
100
200
300
400
500
600
HepG2
Rat hepatocytes
Human hepatocytes
[Valproate] (M)
L
ip
id
 r
at
io
 (
%
 o
f 
co
n
tr
o
l)
 
Fig. 12. Valproate-induced variations in lipid content after long exposure 
flow cytometry as mentioned above. Results are expressed as a percentage of the control 
value (solvent-treated cells) and correspond to the mean ± SD of 2 replicates. Sigmoidal 
curve fitting was performed with GraphPad Prism software. 
The accumulation of neutral lipids (evidenced by an increase in lipid ratio) is much more 
pronounced in HepG2 cells than in primary hepatocytes, with human hepatocytes 
exhibiting the smallest amplitude of variation. This is probably due to the fact that the basal 
content in neutral lipids (in vehicle-treated condition) varies considerably between cell types 
(i.e. the lipid ratio is higher in primary hepatocytes than in HepG2 cells). 
Variations in neutral lipid content and polar lipid content were also examined separately to 
corroborate that the observed VPA-induced augmentation in lipid ratio corresponds to an 
increase in neutral lipids (and not a decrease in phospholipids content). The same 
experiment was performed using amiodarone, an antiarrhythmic drug which induces both 
phospholipidosis and steatosis (Fig. 13). 
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Fig. 13. Steatosis and phospholipidosis in HepG2 cells 
HepG2 cells were incubated for 72 h with increasing concentrations of valproate or 
amiodarone. The fluorescence intensities of the neutral lipids and the polar lipids stainings 
were quantified in high-throughput flow cytometry as mentioned above. Fluorescence 
intensity is expressed as a percentage of the control value (solvent-treated cells). Data are 
given as mean ± SD of 2 replicates. Sigmoidal curve fitting was performed with GraphPad 
Prism software. 
As expected, VPA caused an increase in neutral lipid content with no effect on polar lipid 
content whereas amiodarone elicited an increase in phospholipids and a smaller rise in 
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neutral lipid content. These results are in accordance with published data reporting that 
although amiodarone induces both phospholipidosis and steatosis, the accumulation of 
phospholipids appears after a shorter exposure than those required to provoke an 
accumulation of neutral lipids (Antherieu et al., 2011).  
The lipid assay was subsequently applied to tetracycline, a broad-spectrum antibiotic which 
inhibits protein synthesis by binding to the 30S subunit of microbial ribosomes. Tetracycline 
hepatotoxicity seems related to the use of large doses and unlike most other antibiotics, is 
predictable and reproducible in animal models. With normal low oral doses, tetracycline 
only rarely causes liver injury. Intravenous or large oral doses of tetracycline induce 
microvesicular steatosis most likely by direct inhibition of mitochondrial beta-oxidation 
enzyme(s) (Donato et al, 2009). In our assay, variations in lipid content are detected in cells 
incubated with sub-cytotoxic concentrations of tetracycline (Fig. 14). 
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Fig. 14. Variations in lipid content “precede” mitochondrial depolarization 
Primary rat hepatocytes were incubated for 48 h with increasing concentrations of 
tetracycline. Variations in lipid content were assessed by measuring the single cell lipid ratio 
and results are expressed as a percentage of the control value (solvent-treated cells). Both 
lipid content and mitochondrial membrane depolarization assays were performed in high-
throughput flow cytometry as mentioned above. Results are expressed as the mean ± SD of 
2 replicates. Sigmoidal curve fitting was performed with GraphPad Prism software. 
Our optimized lipid assay can thus be useful for detecting variations in lipid content with a 
high sensitivity (thanks to the use of a lipid ratio), and for determining drugs mechanism of 
action (steatosis and/or phospholipidosis). 
6. Idiosyncratic DILI prediction 
Although most of the toxic candidate compounds are screened out during preclinical safety 
studies, each year several new drugs do not get approval or are withdrawn from the market 
because their toxicity is detected only in late clinical phases or in postmarketing evaluation. 
Idiosyncratic drug-induced liver injury (DILI) refers to severe (and potentially fatal) hepatic 
reactions with a low frequency of occurrence (<0.1%), that do not occur in most patients at 
any dose of the drug, and typically have a delayed onset of weeks or months after initial 
exposure. Examples of drugs withdrawn from the market because of idiosyncratic DILI 
include troglitazone and alpidem. In order to assess whether the assays we developed could 
prove useful for the identification of drugs with an idiosyncratic hepatotoxic potential, we 
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tested pairs of compounds which are related in chemical structure and mechanism of action 
but show marked differences in hepatotoxic potential. 
First we tested troglitazone and rosiglitazone, two antidiabetic drugs that belong to the 
thiazolidinedione family. As mentioned above, troglitazone was withdrawn from the 
market because of idiosyncratic DILI and was replaced by newer thiazolidinediones 
(including rosiglitazone) with diminished incidence of hepatotoxicity. In HepG2 cells, both 
drugs produced ROS although a marked effect was obtained with 40 µM of troglitazone 
whereas 200 µM of rosiglitazone were required to induce an equivalent ROS production 
(Fig. 15). These results are consistent with published data reporting that 50 µM troglitazone 
induced ROS production in another human hepatocytes cell line (Shishido et al., 2003). Cell 
death was only evidenced at the highest tested dose of troglitazone, and a similar GSH 
depletion was observed with both drugs. In addition, alterations in lipid content were much 
more pronounced with troglitazone than with rosiglitazone. 
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Fig. 15. Multiparametric assessment of troglitazone and rosiglitazone effects in HepG2 cells 
HepG2 cells were incubated for 72 h with the indicated concentrations of troglitazone and 
rosiglitazone. Cell death, ROS production, GSH depletion and lipid content were assessed in 
high-throughput flow cytometry as mentioned above. Results are expressed as the mean ± 
SD of 2 replicates. 
Our assays were also applied to one pair of drugs from the imidazopyridine class, namely 
alpidem (a “DILI positive” compound) and zolpidem (a “DILI negative” compound). 
Although alpidem is related to the better known sleeping medication zolpidem, it does not 
produce sedative effects at normal doses and was thus used specifically for the treatment of 
anxiety. Alpidem was released in France in 1991 but was withdrawn from the market a few 
years later because several cases of severe hepatitis had been reported. The test of these 
drugs in HepG2 cells (Fig. 16) revealed that neither alpidem nor zolpidem induced ROS 
production, even at high concentrations. In contrast, as previously reported in rat 
hepatocytes, both drugs reduced GSH content, with alpidem exhibiting more pronounced 
effects than zolpidem (Berson et al., 2001). Cell death was apparent only after treatment with 
alpidem, but not zolpidem. Finally, a very significant increase in lipid ratio was measured at 
low sub-cytotoxic concentrations of alpidem (2 µM) whereas no effect was observed with 
equimolar concentrations of zolpidem. 
HepG2 cells were incubated for 72 h with the indicated concentrations of alpidem and 
zolpidem. Cell death, ROS production, GSH depletion and lipid content were assessed in 
high-throughput flow cytometry as mentioned above. Results are expressed as the mean ± 
SD of 2 replicates. 
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Fig. 16. Multiparametric assessment of alpidem and zolpidem effects in HepG2 cells 
All together these data show that the tested drug pairs have very different profiles in our 
assays. In particular alterations in lipid content seem to be a good indicator of the 
idiosyncratic hepatotoxic potential of a drug. Our tests could certainly be of great value in 
preclinical studies, in particular for safety-based prioritization of compounds. 
7. Conclusion 
Thanks to an extensive optimization, high quality measurement of endpoints could be 
obtained in all 3 hepatic cellular models: the HepG2 cell line, freshly isolated rat hepatocytes 
and cryopreserved human hepatocytes. The good quality of these measurements, and in 
particular the low experimental variability, allowed the detection of small variations in the 
measured parameters. Combined with the use of early intracellular indicators of 
hepatotoxicity, we could detect cell alterations at much lower concentrations than those 
needed for gross cytotoxicity. Moreover these measurements could be performed at high 
throughput with a flow cytometry platform by multiplexing the assays in 96-well plates and 
using only 2 replicates per experimental condition. 
As expected with a cell line, HepG2 cells generated reproducible results with very low 
variability. For all the assays we developed, the results obtained with these cells also had an 
extended dynamic range, indicative of the excellent technical performance of the described 
assays. However, probably in part due to their reduced drug metabolizing activity, the 
response of these cells to certain compounds differed from the one obtained in primary 
hepatocytes. Therefore HepG2 cells are not the most adequate cellular model to elucidate 
drug toxicity mechanism of action. However, these cells have prove useful for particular 
studies such as the analysis of drug-induced alterations in lipid content (steatosis and 
phospholipidosis), and the prioritization of compounds based on their potential to cause 
liver injury. 
Measurements performed with primary cells have a higher variability (in comparison with 
HepG2 cells) but which is still quite low and compatible with the use of duplicates. In 
primary hepatocytes, the dynamic range of certain assays is also reduced compared to 
HepG2 cells, in particular for human hepatocytes. This is largely due to the low basal 
viability (in untreated conditions) of cryopreserved human hepatocytes, after several days in 
culture. As a result, although human hepatocytes theoretically represent the best cellular 
model, the use of frozen hepatocytes with a reduced viability and the lot-to-lot variability 
constitute limiting factors for their utilization in large scale screening studies. These cells 
appear to be more suited to mechanistic studies.  
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As a cellular model for liver toxicity studies, freshly isolated rat hepatocytes represent a 
good compromise in terms of cell availability and handling, quality of the results 
(experimental variability, dynamic range and reproducibility), and hepato-specific 
differentiation and functionality.  
In summary, the individual assays we developed can provide insights into the underlying 
mechanism of action of drug-induced hepatotoxicity and we are currently evaluating 
whether combinations of these assays could be routinely used early in the drug 
development process for the prediction of acute hepatotoxicity or the prioritization of 
compounds based on their potential to cause idiosyncratic liver toxicity. 
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